NPPB and atrial fibrillation: In this study, levosimendan compared with placebo did show improvement in symptoms at 5 days, reduction in NT-ProBNP levels, and shorter hospitalization duration, but these benefits were accompanied by an increase in adverse events such as hypotension, ventricular tachycardia, and atrial fibrillation.